Safety syringe market seen reaching $14.77 billion by 2030

The global safety syringe market is projected to grow from $10.52 billion in 2026 to $14.77 billion by 2030, driven by demand for safer injection practices and efforts to reduce needle-stick injuries. North America led the market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Safety syringes are designed to reduce needle-stick injuries and prevent reuse, which supports infection control and occupational safety in healthcare settings. - Rising blood-borne disease awareness and tighter injection safety rules are expanding demand across hospitals, clinics, long-term care, and ambulatory surgical centers.

What happened: - The Business Research Company projected the global safety syringe market will rise from $9.68 billion in 2025 to $10.52 billion in 2026. - The firm said the market is forecast to reach $14.77 billion by 2030, equal to an 8.8% compound annual growth rate. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Growth drivers include rising needle-stick injuries among healthcare workers, stricter regulations on safe injection practices and single-use devices, and wider hospital immunization programs. - Demand is also rising for automatic and manual retractable safety syringes. - The market is gaining use in insulin delivery, clp-i tuberculosis treatments and growth hormone therapies. - Adoption is expanding in ambulatory surgical centers and specialty clinics. - Procurement is increasing in long-term care and chronic disease management. - The report flagged stronger efforts to prevent device reuse and cross-contamination. - Key trends include a rising preference for retractable designs and broader use in subcutaneous and intramuscular drug administration. - The company added new 2026 report features including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics. - A free sample report is available here. - The full report is available here.

Between the lines: - Blood-borne disease testing is reinforcing the case for safety syringes, especially in settings where exposure risk is higher. - The UK Health Security Agency said in November 2024 that 34 emergency departments in the UK carried out nearly two million HIV tests, about 1.5 million hepatitis C tests and more than 1.1 million hepatitis B tests over 24 months. - That testing volume underscores how infection control has become a bigger operational priority for healthcare providers.

What's next: - Market growth is likely to stay tied to regulatory pressure, safer device design and wider use in chronic disease care. - Asia-Pacific’s growth trajectory could narrow the gap with North America as healthcare systems expand procurement and safety standards. - Wider deployment of retractable syringes could shape product competition through 2030.

The bottom line: - The safety syringe market is moving from a niche safety category to a broader infection-control tool with long-term growth built into healthcare policy, clinical demand and device design.